Results 21 to 30 of about 6,788,532 (255)

Review: ‘Gimme five’: future challenges in multiple sclerosis. ECTRIMS Lecture 2009 [PDF]

, 2010
This article is based on the ECTRIMS lecture given at the 25th ECTRIMS meeting which was held in Düsseldorf, Germany, from 9 to 12 September 2009. Five challenges have been identified: (1) safeguarding the principles of medical ethics; (2) optimizing the
Bartholomaus I., Ben-Nun A., Bennett JL, Bielekova B., Bradl M., Chabas D., De Jager PL, De Jager PL, Dornmair K., Ferguson B., Flügel A., Frischer JM, Gold R., Gregersen JW, Han MH, Hohlfeld R., Hohlfeld R., Junker A., Kerschensteiner M., Kerschensteiner M., Kinoshita M., Korn T., Krishnamoorthy G., Kuhlmann T., Kümpfel T., Kümpfel T., Kümpfel T., Lennon VA, Linington C., Lock C., Mathey EK, Misgeld T., Platten M., Pollinger B., Polman CH, Reinhard Hohlfeld, Schluesener HJ, Seitz S., Sobottka B., Stadelmann C., Trapp BD, Trapp BD, Wiendl H., Wiendl H., Zipp F.   +44 more
core   +1 more source

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

Annals of Neurology, 2011
New evidence and consensus has led to further revision of the McDonald Criteria for diagnosis of multiple sclerosis. The use of imaging for demonstration of dissemination of central nervous system lesions in space and time has been simplified, and in ...
C. Polman, S. Reingold, B. Banwell, M. Clanet, Jeffrey A. Cohen, M. Filippi, K. Fujihara, E. Havrdová, M. Hutchinson, L. Kappos, F. Lublin, X. Montalban, P. O'Connor, M. Sandberg-wollheim, A. Thompson, E. Waubant, B. Weinshenker, J. Wolinsky   +17 more
semanticscholar   +1 more source

Ageing and multiple sclerosis.

Lancet Neurology, 2022
The factor that is most relevant and strongly associated with the clinical course of multiple sclerosis is chronological age. Very young patients exclusively have relapsing remitting disease, whereas those with later onset disease face a more rapid ...
J. Graves, K. Krysko, L. Hua, M. Absinta, R. Franklin, B. Segal   +5 more
semanticscholar   +1 more source

No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]

Neurology and Therapy, 2023
The emergence of high-efficacy therapies for multiple sclerosis (MS), which target inflammation more effectively than traditional disease-modifying therapies, has led to a shift in MS management towards achieving the outcome assessment known as no ...
Scott D. Newsome, Cherie Binns, Ulrike W. Kaunzner, Seth Morgan, June Halper   +4 more
doaj   +1 more source

Author Correction: A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis

Nature Communications, 2019
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
International Multiple Sclerosis Genetics Consortium
doaj   +1 more source

Real-World Efficacy of COVID-19 Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab in People with Multiple Sclerosis

Vaccines, 2023
Vaccines against the SARS-CoV-2 virus were authorized for use by the Food and Drug Administration (FDA) in the United States and have proven effective for the prevention of morbidity and death from COVID-19.
Luke B. Elias, Aliya Jaber, Margarita Manzano, Mark Leekoff, Andrew Sylvester, Matthew A. Tremblay   +5 more
doaj   +1 more source

Multiple Sclerosis and Schizophrenia [PDF]

, 2017
The psychiatric and neurological aspects of health may present methodological challenges in the diagnosis and treatment of disease. This is especially true for patients whose symptoms indicate the coexistence of multiple sclerosis (MS) and schizophrenia (
Arneth, Borros M
core   +1 more source

Using normalisation process theory to understand barriers and facilitators to implementing mindfulness-based stress reduction for people with multiple sclerosis [PDF]

, 2018
Objectives: To study barriers and facilitators to implementation of mindfulness-based stress reduction for people with multiple sclerosis. Methods: Qualitative interviews were used to explore barriers and facilitators to implementation of ...
Mair, Frances S., Mercer, Stewart W., Simpson, Robert, Simpson, Sharon, Wood, Karen   +4 more
core   +1 more source

Family Perspectives on Clinical Research for Pediatric Multiple Sclerosis: Enhancing Equity

Journal of Patient Experience, 2021
Pediatric new drug trials are federally mandated, but family perspectives in multiple sclerosis (MS) research are limited. Due to MS chronicity and long-term medical system involvement, we obtained family views on research priorities and optimized ...
Leslie A Mandel PhD, MA, MS, Ellen O’Donnell PhD, Katia Canenguez PhD, EdM, Paola B Castro-Mendoza BSc, MSc, Tim Lotze MD, Emmanuelle Waubant MD, PhD, Bianca Weinstock-Guttmann MD, Tanuja Chitnis MD   +7 more
doaj   +1 more source

Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study

Frontiers in Neurology, 2023
BackgroundAlemtuzumab (ALZ) is a humanized monoclonal antibody approved for the treatment of patients with highly active relapsing-remitting multiple sclerosis (RRMS) administered in two annual courses.
Sara Eichau, Rocío López Ruiz, María Ruíz de Arcos, Juan Luis Ruiz-Peña, Guillermo Navarro, Miguel Ángel Calleja, José Luis Moreno-Amador, Julio Dotor García-Soto   +7 more
doaj   +1 more source